Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 13/20 | 0.68 |
| ▸ | CCR6 | P51684 | 4/20 | 0.61 |
| ▸ | CXCR1 | P25024 | 8/20 | 0.43 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.42 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | CCR7 | P32248 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406883 | 0.95 | CCR6 (0.69) | CXCR2CCR6CXCR1TAS1R3TAS1R1 | |
| SCHEMBL13406875 | 0.81 | CXCR2 (0.65) | CXCR2CCR6CXCR1 | |
| SCHEMBL12262523 | 0.81 | CXCR2 (1.00) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL13406876 | 0.81 | CXCR2 (0.66) | CXCR2CCR6CXCR1 | |
| SCHEMBL13405675 | 0.78 | CXCR2 (0.63) | CXCR2CCR6CXCR1 | |
| SCHEMBL12262467 | 0.76 | CCR6 (1.00) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL20721281 | 0.76 | CCR6 (1.00) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL12087174 | 0.76 | CCR6 (1.00) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL13407269 | 0.75 | CXCR2 (0.53) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL13406984 | 0.75 | CXCR2 (0.67) | CXCR2CCR6CXCR1CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | CXCR2 6/4885CCR6 24/4885CXCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.